Cargando…

Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma

BACKGROUND: Treatment options for unresectable new and recurrent glioblastoma remain limited. Laser ablation has demonstrated safety as a surgical approach to treating primary brain tumors. The LAANTERN prospective multicenter registry (NCT02392078) data were analyzed to determine clinical outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales: de Groot, John F, Kim, Albert H, Prabhu, Sujit, Rao, Ganesh, Laxton, Adrian W, Fecci, Peter E, O’Brien, Barbara J, Sloan, Andrew, Chiang, Veronica, Tatter, Stephen B, Mohammadi, Alireza M, Placantonakis, Dimitris G, Strowd, Roy E, Chen, Clark, Hadjipanayis, Constantinos, Khasraw, Mustafa, Sun, David, Piccioni, David, Sinicrope, Kaylyn D, Campian, Jian L, Kurz, Sylvia C, Williams, Brian, Smith, Kris, Tovar-Spinoza, Zulma, Leuthardt, Eric C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122789/
https://www.ncbi.nlm.nih.gov/pubmed/35611270
http://dx.doi.org/10.1093/noajnl/vdac040
_version_ 1784711419231469568
author de Groot, John F
Kim, Albert H
Prabhu, Sujit
Rao, Ganesh
Laxton, Adrian W
Fecci, Peter E
O’Brien, Barbara J
Sloan, Andrew
Chiang, Veronica
Tatter, Stephen B
Mohammadi, Alireza M
Placantonakis, Dimitris G
Strowd, Roy E
Chen, Clark
Hadjipanayis, Constantinos
Khasraw, Mustafa
Sun, David
Piccioni, David
Sinicrope, Kaylyn D
Campian, Jian L
Kurz, Sylvia C
Williams, Brian
Smith, Kris
Tovar-Spinoza, Zulma
Leuthardt, Eric C
author_facet de Groot, John F
Kim, Albert H
Prabhu, Sujit
Rao, Ganesh
Laxton, Adrian W
Fecci, Peter E
O’Brien, Barbara J
Sloan, Andrew
Chiang, Veronica
Tatter, Stephen B
Mohammadi, Alireza M
Placantonakis, Dimitris G
Strowd, Roy E
Chen, Clark
Hadjipanayis, Constantinos
Khasraw, Mustafa
Sun, David
Piccioni, David
Sinicrope, Kaylyn D
Campian, Jian L
Kurz, Sylvia C
Williams, Brian
Smith, Kris
Tovar-Spinoza, Zulma
Leuthardt, Eric C
author_sort de Groot, John F
collection PubMed
description BACKGROUND: Treatment options for unresectable new and recurrent glioblastoma remain limited. Laser ablation has demonstrated safety as a surgical approach to treating primary brain tumors. The LAANTERN prospective multicenter registry (NCT02392078) data were analyzed to determine clinical outcomes for patients with new and recurrent IDH wild-type glioblastoma. METHODS: Demographics, intraprocedural data, adverse events, KPS, health economics, and survival data were prospectively collected and then analyzed on IDH wild-type newly diagnosed and recurrent glioblastoma patients who were treated with laser ablation at 14 US centers between January 2016 and May 2019. Data were monitored for accuracy. Statistical analysis included individual variable summaries, multivariable differences in survival, and median survival numbers. RESULTS: A total of 29 new and 60 recurrent IDH wild-type WHO grade 4 glioblastoma patients were treated. Positive MGMT promoter methylation status was present in 5/29 of new and 23/60 of recurrent patients. Median physician-estimated extent of ablation was 91%-99%. Median overall survival (OS) was 9.73 months (95% confidence interval: 5.16, 15.91) for newly diagnosed patients and median post-procedure survival was 8.97 months (6.94, 12.36) for recurrent patients. Median OS for newly diagnosed patients receiving post-LITT chemo/radiation was 16.14 months (6.11, not reached). Factors associated with improved survival were MGMT promoter methylation, adjuvant chemotherapy within 12 weeks, and tumor volume <3 cc. CONCLUSIONS: Laser ablation is a viable option for patients with new and recurrent glioblastoma. Median OS for IDH wild-type newly diagnosed glioblastoma is comparable to outcomes observed in other tumor resection studies when those patients undergo radiation and chemotherapy following LITT.
format Online
Article
Text
id pubmed-9122789
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-91227892022-05-23 Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma de Groot, John F Kim, Albert H Prabhu, Sujit Rao, Ganesh Laxton, Adrian W Fecci, Peter E O’Brien, Barbara J Sloan, Andrew Chiang, Veronica Tatter, Stephen B Mohammadi, Alireza M Placantonakis, Dimitris G Strowd, Roy E Chen, Clark Hadjipanayis, Constantinos Khasraw, Mustafa Sun, David Piccioni, David Sinicrope, Kaylyn D Campian, Jian L Kurz, Sylvia C Williams, Brian Smith, Kris Tovar-Spinoza, Zulma Leuthardt, Eric C Neurooncol Adv Clinical Investigations BACKGROUND: Treatment options for unresectable new and recurrent glioblastoma remain limited. Laser ablation has demonstrated safety as a surgical approach to treating primary brain tumors. The LAANTERN prospective multicenter registry (NCT02392078) data were analyzed to determine clinical outcomes for patients with new and recurrent IDH wild-type glioblastoma. METHODS: Demographics, intraprocedural data, adverse events, KPS, health economics, and survival data were prospectively collected and then analyzed on IDH wild-type newly diagnosed and recurrent glioblastoma patients who were treated with laser ablation at 14 US centers between January 2016 and May 2019. Data were monitored for accuracy. Statistical analysis included individual variable summaries, multivariable differences in survival, and median survival numbers. RESULTS: A total of 29 new and 60 recurrent IDH wild-type WHO grade 4 glioblastoma patients were treated. Positive MGMT promoter methylation status was present in 5/29 of new and 23/60 of recurrent patients. Median physician-estimated extent of ablation was 91%-99%. Median overall survival (OS) was 9.73 months (95% confidence interval: 5.16, 15.91) for newly diagnosed patients and median post-procedure survival was 8.97 months (6.94, 12.36) for recurrent patients. Median OS for newly diagnosed patients receiving post-LITT chemo/radiation was 16.14 months (6.11, not reached). Factors associated with improved survival were MGMT promoter methylation, adjuvant chemotherapy within 12 weeks, and tumor volume <3 cc. CONCLUSIONS: Laser ablation is a viable option for patients with new and recurrent glioblastoma. Median OS for IDH wild-type newly diagnosed glioblastoma is comparable to outcomes observed in other tumor resection studies when those patients undergo radiation and chemotherapy following LITT. Oxford University Press 2022-04-06 /pmc/articles/PMC9122789/ /pubmed/35611270 http://dx.doi.org/10.1093/noajnl/vdac040 Text en © The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Investigations
de Groot, John F
Kim, Albert H
Prabhu, Sujit
Rao, Ganesh
Laxton, Adrian W
Fecci, Peter E
O’Brien, Barbara J
Sloan, Andrew
Chiang, Veronica
Tatter, Stephen B
Mohammadi, Alireza M
Placantonakis, Dimitris G
Strowd, Roy E
Chen, Clark
Hadjipanayis, Constantinos
Khasraw, Mustafa
Sun, David
Piccioni, David
Sinicrope, Kaylyn D
Campian, Jian L
Kurz, Sylvia C
Williams, Brian
Smith, Kris
Tovar-Spinoza, Zulma
Leuthardt, Eric C
Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma
title Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma
title_full Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma
title_fullStr Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma
title_full_unstemmed Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma
title_short Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma
title_sort efficacy of laser interstitial thermal therapy (litt) for newly diagnosed and recurrent idh wild-type glioblastoma
topic Clinical Investigations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122789/
https://www.ncbi.nlm.nih.gov/pubmed/35611270
http://dx.doi.org/10.1093/noajnl/vdac040
work_keys_str_mv AT degrootjohnf efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma
AT kimalberth efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma
AT prabhusujit efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma
AT raoganesh efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma
AT laxtonadrianw efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma
AT feccipetere efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma
AT obrienbarbaraj efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma
AT sloanandrew efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma
AT chiangveronica efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma
AT tatterstephenb efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma
AT mohammadialirezam efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma
AT placantonakisdimitrisg efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma
AT strowdroye efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma
AT chenclark efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma
AT hadjipanayisconstantinos efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma
AT khasrawmustafa efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma
AT sundavid efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma
AT piccionidavid efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma
AT sinicropekaylynd efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma
AT campianjianl efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma
AT kurzsylviac efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma
AT williamsbrian efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma
AT smithkris efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma
AT tovarspinozazulma efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma
AT leuthardtericc efficacyoflaserinterstitialthermaltherapylittfornewlydiagnosedandrecurrentidhwildtypeglioblastoma